Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | HINT1 | P49773 | 2/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898731 | 0.89 | TYMP (0.51) | TYMPHPGDXDHTAAR1HINT1 | |
| SCHEMBL19356965 | 0.87 | TYMP (0.44) | TYMPHPGDTAAR1HINT1TAS1R3 | |
| SCHEMBL30141048 | 0.87 | TYMP (0.44) | TYMPHINT1 | |
| SCHEMBL19362152 | 0.87 | TYMP (0.45) | TYMPHPGDTAAR1TAS1R3TAS1R1 | |
| SCHEMBL22556249 | 0.87 | TYMP (0.45) | TYMPHPGD | |
| SCHEMBL24513002 | 0.87 | TYMP (0.45) | TYMPHPGDTAAR1TAS1R3TAS1R1 | |
| SCHEMBL22594612 | 0.87 | TYMP (0.45) | TYMPHPGD | |
| SCHEMBL22556252 | 0.87 | TYMP (0.45) | TYMPHPGD | |
| SCHEMBL31359570 | 0.87 | TYMP (0.45) | TYMPHPGD | |
| SCHEMBL1096942 | 0.87 | TYMP (0.45) | TYMPHPGDTAAR1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| EP-4370136-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023288045-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025564-A1 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ADAR, ADA, NUDT1 | TYMP 76/4885HPGD 1764/4885XDH 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.